Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | DAO | P14920 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL28672871 | 1.00 | TSHR (0.67) | TSHRDAONAPRTSRD5A2CES2 | |
| Benzoic Acid SCHEMBL5085720 | 0.95 | TSHR (0.67) | TSHRDAONAPRTSRD5A2CES2 | |
| Benzoic Acid SCHEMBL5085787 | 0.89 | TSHR (0.58) | TSHRDAONAPRTSRD5A2CES2 | |
| Isophthalic Acid SCHEMBL7568507 | 0.89 | FOLH1 (0.60) | TSHRDAONAPRTNR4A2FOLH1 | |
| Benzoic Acid SCHEMBL28180857 | 0.88 | TSHR (0.52) | TSHRDAONAPRTSRD5A2CES2 | |
| Paraben SCHEMBL27820033 | 0.87 | CA12 (0.64) | TSHRDAONAPRTSRD5A2CES2 | |
| Benzoic Acid SCHEMBL27884239 | 0.87 | CA2 (0.58) | TSHRDAONAPRTSRD5A2CES2 | |
| Benzoic Acid SCHEMBL29163749 | 0.87 | EPHX2 (0.57) | TSHRDAONAPRTSRD5A2CES2 | |
| Benzophenone SCHEMBL27760924 | 0.86 | ALDH1A1 (0.67) | TSHRSRD5A2MDM2KMT2ATDP1 | |
| 4-Methylbenzoic Acid SCHEMBL28711761 | 0.86 | SMN1; SMN2 (0.65) | TSHRDAONAPRTSRD5A2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992469-B2 | Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury | CITY UNIVERSITY OF HONG KONG (CN) | 2024-05-28 | — | — | US | disclosed |
| US-20240110853-A1 | METHOD FOR OPTICALLY CLEARING A TISSUE SAMPLE USING AN EMBEDDING MEDIUM | MobiCron GmbH (DE) | 2024-04-04 | — | — | US | disclosed |
| US-20240110853-A1 | METHOD FOR OPTICALLY CLEARING A TISSUE SAMPLE USING AN EMBEDDING MEDIUM | MobiCron GmbH (DE) | 2024-04-04 | — | — | US | disclosed |
| US-20240102898-A1 | IMPROVED METHOD FOR OPTICALLY CLEARING A TISSUE SAMPLE FOR A LIGHT MICROSCOPY EXAMINATION | MobiCron GmbH (DE) | 2024-03-28 | — | — | US | disclosed |
| US-20240102898-A1 | IMPROVED METHOD FOR OPTICALLY CLEARING A TISSUE SAMPLE FOR A LIGHT MICROSCOPY EXAMINATION | MobiCron GmbH (DE) | 2024-03-28 | — | — | US | disclosed |
| CN-116802492-A | Improved optical transparency method for tissue samples for optical microscopy | 摩比空公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116802492-A | Improved optical transparency method for tissue samples for optical microscopy | 摩比空公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11759451-B2 | Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury | CITY UNIVERSITY OF HONG KONG (CN) | 2023-09-19 | — | — | US | disclosed |
| CN-116635717-A | Method for optically transparentizing tissue samples using embedding medium | 摩比空公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116635717-A | Method for optically transparentizing tissue samples using embedding medium | 摩比空公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2002059270-A2 | METHODS AND COMPOSITIONS FOR EXPRESSING POLYNUCLEOTIDES SPECIFICALLY IN SMOOTH MUSCLE CELLS IN VIVO | SETAGON, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0877802-A4 | NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS | HUTCHINSON FRED CANCER RES (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-0759938-A4 | NEUROGENIC DIFFERENTIATION (NEUROD) GENES AND PROTEINS | HUTCHINSON FRED CANCER RES (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1999007725-A1 | EXPRESSION OF NEUROGENIC bHLH GENES IN PRIMITIVE NEUROECTODERMAL TUMORS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0877802-A1 | NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS | Fred Hutchinson Cancer Research Center (US) | 1998-11-18 | — | — | EP | disclosed |
| US-5795723-A | MEASURING TRANSCRIPTS OR PROTEINS EXPRESEDFROM GENES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1998-08-18 | — | — | US | disclosed |
| US-5695995-A | HYBRID POLYNUCLEOTIDES ENCODING A NEUROGENIC DIFFERENTIATION PROTEINS; GENE THERAPY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997016548-A1 | NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1997-05-09 | — | — | WO | disclosed |
| EP-0759938-A1 | NEUROGENIC DIFFERENTIATION (NEUROD) GENES AND PROTEINS | Fred Hutchinson Cancer Research Center (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995030693-A1 | NEUROGENIC DIFFERENTIATION (NEUROD) GENES AND PROTEINS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992469-B2 | Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury | MFN2, NLN, TFAM | TSHR 4180/4885DAO 2592/4885NAPRT 3149/4885 |
| US-11759451-B2 | Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury | GAP43, GYPA, PMP22 | TSHR 1572/4885DAO 1890/4885NAPRT 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.